Sanofi (SNY)
SNY Stock Price Chart
Explore Sanofi interactive price chart. Choose custom timeframes to analyze SNY price movements and trends.
SNY Company Profile
Discover essential business fundamentals and corporate details for Sanofi (SNY) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - General
IPO Date
1 Jul 2002
Employees
82.88k
Website
https://www.sanofi.comCEO
Olivier Charmeil
Description
Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.
SNY Financial Timeline
Browse a chronological timeline of Sanofi corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 30 Jul 2026
EPS estimate is $1.09, while revenue estimate is $12.76bn.
Dividend declared on 4 May 2026
A dividend of $2.42 per share was announced, adjusted to $2.42. The dividend was paid on 3 Jun 2026.
Earnings released on 23 Apr 2026
EPS came in at $1.10 surpassing the estimated $1.06 by +3.77%, while revenue for the quarter reached $12.94bn , beating expectations by +2.09%.
Earnings released on 29 Jan 2026
EPS came in at $0.89 surpassing the estimated $0.84 by +5.95%, while revenue for the quarter reached $14.34bn , beating expectations by +22.38%.
Earnings released on 24 Oct 2025
EPS came in at $1.70 surpassing the estimated $1.60 by +6.25%, while revenue for the quarter reached $15.43bn , beating expectations by +38.89%.
Earnings released on 31 Jul 2025
EPS came in at $0.90 falling short of the estimated $0.96 by -6.25%, while revenue for the quarter reached $12.64bn , beating expectations by +2.28%.
Dividend declared on 9 May 2025
A dividend of $2.20 per share was announced, adjusted to $2.20. The dividend was paid on 12 Jun 2025.
Earnings released on 24 Apr 2025
EPS came in at $0.94 surpassing the estimated $0.90 by +4.44%, while revenue for the quarter reached $11.63bn , beating expectations by +16.31%.
Earnings released on 30 Jan 2025
EPS came in at $0.70 falling short of the estimated $0.71 by -1.41%, while revenue for the quarter reached $7.90bn , missing expectations by -16.89%.
Earnings released on 25 Oct 2024
EPS came in at $1.57 surpassing the estimated $1.35 by +16.30%, while revenue for the quarter reached $15.53bn , beating expectations by +11.39%.
Earnings released on 25 Jul 2024
EPS came in at $0.93 surpassing the estimated $0.86 by +8.14%, while revenue for the quarter reached $12.24bn , missing expectations by -17.11%.
Dividend declared on 9 May 2024
A dividend of $2.04 per share was announced, adjusted to $2.04. The dividend was paid on 6 Jun 2024.
Earnings released on 25 Apr 2024
EPS came in at $0.97 surpassing the estimated $0.94 by +3.19%, while revenue for the quarter reached $11.94bn .
Earnings released on 1 Feb 2024
EPS came in at $0.89 falling short of the estimated $0.94 by -5.32%, while revenue for the quarter reached $25.17bn .
Earnings released on 27 Oct 2023
EPS came in at $1.39 surpassing the estimated $1.37 by +1.46%, while revenue for the quarter reached $13.39bn .
Earnings released on 28 Jul 2023
EPS came in at $0.95 falling short of the estimated $1.55 by -38.71%, while revenue for the quarter reached $11.65bn .
Dividend declared on 30 May 2023
A dividend of $1.90 per share was announced, adjusted to $1.90. The dividend was paid on 23 Jun 2023.
Earnings released on 27 Apr 2023
EPS came in at $1.16 surpassing the estimated $1.10 by +5.45%, while revenue for the quarter reached $11.81bn .
Earnings released on 3 Feb 2023
EPS came in at $0.87 falling short of the estimated $0.90 by -3.33%, while revenue for the quarter reached $12.34bn , beating expectations by +7.32%.
Earnings released on 28 Oct 2022
EPS came in at $1.44 surpassing the estimated $1.34 by +7.46%, while revenue for the quarter reached $12.83bn , beating expectations by +10.31%.
Earnings released on 28 Jul 2022
EPS came in at $0.92 surpassing the estimated $0.87 by +5.75%, while revenue for the quarter reached $11.24bn , beating expectations by +12.33%.
Dividend declared on 26 May 2022
A dividend of $0.30 per share was announced, adjusted to $0.30. The dividend was paid on 27 Jun 2022.
Dividend declared on 4 May 2022
A dividend of $1.75 per share was announced, adjusted to $1.75. The dividend was paid on 31 May 2022.
Earnings released on 28 Apr 2022
EPS came in at $1.09 surpassing the estimated $0.94 by +15.96%, while revenue for the quarter reached $11.12bn , beating expectations by +10.90%.
Earnings released on 4 Feb 2022
EPS came in at $0.79 surpassing the estimated $0.72 by +9.72%, while revenue for the quarter reached $11.81bn , beating expectations by +2.02%.
Earnings released on 28 Oct 2021
EPS came in at $1.29 surpassing the estimated $1.18 by +9.32%, while revenue for the quarter reached $12.57bn , beating expectations by +4.10%.
Earnings released on 29 Jul 2021
EPS came in at $0.83 surpassing the estimated $0.75 by +10.67%, while revenue for the quarter reached $10.73bn , beating expectations by +1.86%.
SNY Stock Performance
Access detailed SNY performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
